International Journal of Drug Delivery Technology
Volume 15, Issue 3

Evaluation of GATA3 Gene Expression from Urothelial Carcinoma and the Genitourinary System: Its Correlation with Histopathological Parameters

Noor alhuda Sabah Hussain1, Haider Jabur Kehiosh1, Fatima Mutasher Swadi2*

1Alhussain Teaching Hospital, Kerbala, Iraq

2College of Medicine University of Kerbala, Iraq 

Received: 11th Aug, 2024; Revised: 15th Jun, 2025; Accepted: 15th Jul, 2025; Available Online: 25th Sep, 2025 

ABSTRACT

Objective: Evaluation of the GATA3 utility in differentiating urothelial carcinoma from other malignant tumors of the genitourinanry system such as prostatic adenocarcinoma, and renal cell carcinoma. And correlation between GATA3 expression with other different parameters such as grade, stage, necrosis, and mitosis.

Method: 70 cases of urothelial carcinoma, 10 cases of prostatic adenocarcinoma, and 10 cases of renal cell carcinoma of papillary and clear cell variants were selected at the period between (jan. 2017 and sep. 2020), with age range 34 to 88, with mean age 73 years, histopathologically evaluated, then stained with GATA3 antibody, and reevaluated with semi quantitative immunoreactive score, finally GATA3 correlated with tumor grade, stage, necrosis, and mitosis.

Results: In this study GATA3 expressed in 84.3% of urothelial carcinoma cases, Expression used to be considerably correlated with tumor grade; ( p value = 0.001) and stage (p value = 0.003), but not with number of mitosis (p value = 0.2) or necrosis (p value = 0.7), None of the prostatic adenocarcinoma, or renal cell carcinoma express GATA3.

Conclusion: GATA3 could be considered as a necessary precise sensitive and highly specific marker to confirm urothelial origin. It is effective marker if used in the appropriate clinical concepts, GATA3 expression is an independent factor predicting cancer recurrence, so it could be used as a prognostic marker not only diagnostic marker, No significant association found in this study between GATA3 expression and presence or absence of necrosis, or the number of mitosis.

How to cite this article: Noor alhuda Sabah Hussain, Haider Jabur Kehiosh, Fatima Mutasher Swadi. Evaluation of GATA3 Gene Expression from Urothelial Carcinoma and the Genitourinary System: Its Correlation with Histopathological Parameters. International Journal of Drug Delivery Technology. 2025;15(3):1001-05. doi: 10.25258/ijddt.15.3.14

REFERENCES

  1. Szymanska K, T Bosman, F, Hainaut P. Bladder Cancer: Pathology, Genetics, Diagnosis, and Treatment. elsevier. 2019;.
  2. Rana C, Agarwal H, Babu S, Kumar M, Singhai A, Shankhwar S et al. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian Journal of Pathology and Microbiology. 2019;62(2):244.
  3. Mohammed K, Siddiqui M, Cohen C. GATA3 immunohistochemical expression in invasive urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. 2016;34(10):432.e9-432.e13.
  4. Leivo M, Elson P, Tacha D, Delahunt B, Hansel D. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology. 2016;48(6):543-549.
  5. Zhou M, Magi_Galluzi C. Genitourinary Pathology. 2nd ed. 2015. Pages 181 to 247.
  6. Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011;108(11):1800–5.
  7. Bladder cancer and upper tract cancer. Scardino PT, Lineham WM, Zelefsky MJ & Vogelzang NJ (eds.). (2011). Comprehensive Textbook of Genitourinary Oncology. (4th Edition). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. PartII:Chapter15:287- 504.
  8. Cheng L, Weaver AL, Leibovich BC, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer. 2000;88:2326-2332.
  9. Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011;108(11):1800–5.
  10. Hoffmann AC, Wild P, Leicht C et al (2010) MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12:628–636.
  11. Miyamoto H, Izumi K, Yao JL, et al. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol. 2012;43:2033–2040.
  12. Rosai J, Ackerman L, Goldblum J, Lamps L, McKenney J, Myers J. Rosai and Ackerman's surgical pathology. Philadelphia: Elsevier; 2018. Pages 1073 to 1079.
  13. Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994;73:1926–31.
  14. Van Esch H, Groenen P, Nesbit M, Schuffenhauer S, Lichtner P, Vanderlinden G et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature. 2000;406(6794):419-422.
  15. McCleskey BC, Penedo TL, Zhang K, et al. GATA3 Expression in Advanced Breast Cancer Prognostic Value and Organ-Specific Relapse. Am J Clin Pathol. 2015;144:756-763.
  16. Yi Li, Hitoshi Ishiguro,Takashi Kawahara, et al. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014; 4(5): 461–473.
  17. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7-30.
  18. Bostwick DG, Burke HB, Djakiew D, et al. Hum Prostate cancer risk factors. Cancer. 2004;101:2371-2490.
  19. Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S et al. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Human Pathology. 2017;64:83-90.
  20. Peter A. Humphrey, Holger Moch, Antonio L. Cubilla, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. EUROPEAN UROLOGY. 2016; 70:106-119
  21. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol.2014;38(1):13-22.
  22. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 1971;28(5):1165-1177.
  23. Brunelli M, Gobbo S, Menestrina F, et al. Core biopsies of renal tumors: accuracy for histopatholigical evaluation. Lab Invest. 2009;89(suppl 1):161A.
  24. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathol 1987, 8:138–140
  25. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996, 148:1567–1576.